THUR 058 Eslicarbazepine acetate as monotherapy in clinical practice

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

To assess eslicarbazepine acetate (ESL) as monotherapy in everyday clinical practice.

Method

Euro-Esli was a pooled analysis of 14 European studies. In a subanalysis, data were compared for patients treated initially with ESL monotherapy versus adjunctive therapy, and for patients treated at last visit with ESL monotherapy versus adjunctive therapy.

Method

Assessments included responder rate (≥50% seizure frequency reduction), seizure freedom rate (seizure freedom at least since prior visit) and incidence of adverse events (AEs).

Results

ESL was used as monotherapy in 88/2045 and 229/1340 patients initially and at last visit, respectively. At 12 months, responder and seizure freedom rates were significantly higher in patients treated initially with ESL monotherapy versus adjunctive therapy (responder: 94.1% versus 74.8%; seizure freedom: 88.2% versus 39.0%), and in patients treated at last visit with ESL monotherapy versus adjunctive therapy (responder: 93.2% versus 70.4%; seizure freedom: 77.4% versus 25.9%). Overall incidence of AEs was similar in patients treated initially with ESL monotherapy and adjunctive therapy (29.4% versus 34.4%), and in patients treated at last visit with ESL monotherapy and adjunctive therapy (27.1% versus 30.8%).

Conclusion

ESL was significantly more effective when used as monotherapy compared with adjunctive therapy; safety/tolerability was generally comparable.

Conclusion

Supported by Eisai

Related Topics

    loading  Loading Related Articles